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The complement system plays a crucial role in fighting infections
and is an important link between the innate and adaptive immune
responses. However, inappropriate complement activation can
cause tissue damage, and it underlies the pathology of many
diseases. In the transfusion medicine setting, complement
sensitization of RBCs can lead to both intravascular and
extravascular destruction. Moreover, complement deficiencies are
associated with autoimmune disorders, including autoimmune
hemolytic anemia (AIHA). Complement receptor 1 (CR1) is a large
single-pass glycoprotein that is expressed on a variety of cell types
in blood, including RBCs and immune cells. Among its multiple
functions is its ability to inhibit complement activation.
Furthermore, gene knockout studies in mice implicate a role for
CR1 (along with the alternatively spliced gene product CR2) in
prevention of autoimmunity. This review discusses the possibility
that the CR1 protein may be manipulated to prevent and treat
AIHA. In addition, it will be shown in an in vivo mouse model of
transfusion reaction that recombinant soluble forms of CR1 can
reduce complement-mediated RBC destruction, thereby prolonging
survival of transfused RBCs. It is proposed that CR1-based
therapeutics have potential for effective and safe prophylactic
short-term use and for treatment of hemolytic transfusion reactions.
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The Complement System and Red Cell
Destruction
The complement system is an important part of the
innate immune system for fighting infections and
foreign molecules before an adaptive response has
developed.1 It is also an important regulator of B-cell,
and possibly T-cell, immunity.2,3 However, it can also
cause cellular and tissue damage when activated
inappropriately, contributing to many clinical
conditions, including reperfusion injury (following
surgery, ischemic disease, and organ transplantation),
organ rejection,acute inflammatory injury to the lungs,
and autoimmune diseases.1 For the system to exert its
biological activities, it has to be activated. Activation
occurs in a sequence that involves proteolytic cleavage
of the complement components, resulting in the
release of active biological mediators and the assembly
of active enzyme molecules that result in cleavage of
the next downstream complement component.1
Depending on the nature of the activators, three
complement activation pathways have been described:
the antibody-dependent classical pathway and the
antibody-independent alternative and lectin pathways
(Fig. 1).1 Common to all three pathways are two
critical steps: the assembly of the C3 convertase
enzymes and the activation of C5 convertases.
Specifically, the C3 convertases cleave C3 into C3a, a
potent anaphylatoxin, which acts as a neutrophil
chemotaxin and activator,4 and C3b, which covalently
attaches to nearby targets, where it directs immune
clearance and antigen selection.5 In addition, the C5
convertases cause the release of another potent
anaphylatoxin, C5a,4 and lead to the formation of the
pore-like membrane attack complex (C5b-9), which
inserts into cell membranes, causing lysis or sublytic
damage to the target cell (Fig. 1).5
In the transfusion medicine setting, complement-
mediated RBC destruction plays a critical role, being
involved in both intravascular and extravascular
hemolysis.6 Generally, in the presence of a potent,
complement-binding antibody and large numbers of
closely situated RBC antigens, complement activation
can proceed to completion, resulting in intravascular
hemolysis, which can be fatal.7,8 However, the majority
of blood group antibodies (including both alloanti-
bodies and autoantibodies) that can fix complement
activate complement up to the C3 stage but do not go
on to act as hemolysins.9 Although antibody-coated
RBCs can also be destroyed extravascularly without
complement activation, RBC removal by tissue
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macrophages in the spleen and liver is enhanced
considerably when C3 is present on RBCs in addition
to IgG.9,10 Indeed, as many as 50 percent of patients
with autoimmune hemolytic anemia (AIHA) have both
IgG and complement on their RBCs.11
Complement Regulatory Proteins and CR1
The complement system can be divided into three
separate pathways (classical, alternative, and lectin),
depending on the type of activator. The system
consists of nearly 30 different serum and membrane
proteins which, after activation, interact in a highly
regulated enzymatic cascade to generate reaction
products that mediate inflammation and host
protection.1 Because of the direct and indirect
powerful cytolytic activity of complement, there exists
a family of structurally and functionally related
proteins, known as regulators of complement
activation (RCA), that prevent potential host cell
damage from complement activation (Fig. 1).5 CR1,
also known as CD35, is the most versatile of the RCA
family because it exhibits decay-accelerating and
cofactor properties that can inactivate the two critical
enzymes of the complement activation pathways (Fig.
1 and Fig.2).12–15 Specifically,by binding to C4b or C3b,
CR1 can displace the catalytic subunits (decay-
accelerating activity [Fig. 2]) of the convertases. In
addition, by acting as a cofactor for plasma protease
factor I, CR1 is responsible for the degradation of C4b
and C3b (Fig. 2), and thus complete inactivation of the
convertase. CR1 has also been shown to function as a
receptor for C1q,16 the first component of the classical
pathway as well as the mannan-binding lectin (MBL) of
the lectin pathway.17
CR1 Expression Pattern and Functions
CR1 is expressed on a number of cell types, mostly
in the blood, and at low levels in soluble form in the
plasma.18 Of the C4 and C3 regulatory proteins, CR1
has the widest range of activities and functions,
including immune complex clearance, regulation of
complement activation, phagocytosis, and antibody
response, as well as deletion of autoreactive B and
maybe T cells. Through its ability to bind C3b and C4b,
erythrocyte CR1 transports immune complexes to the
spleen and liver for their removal19–23; CR1, expressed
on macrophages and neutrophils, mediates adherence
and phagocytosis24,25; on B cells, CR1 modulates the
threshold for B-cell activation26,27; and on follicular
dendritic cells, it is thought to improve immune
response to antigen.28–36 Through its ability to bind C3b
and C4b, erythrocyte CR1 transports immune
complexes to the spleen and liver for their removal,19–23
CR1 expressed on macrophages and neutrophils
mediates adherence and phagocytosis,24,25 that
expressed on B cells modulates the threshold for B-cell
activation,26,27 and that on follicular dendritic cells is
thought to improve the immune response to
antigen.28–36 Moreover, CR1 is expressed on 10 to 15
percent of human T lymphocytes,37–40 although its
function on such cells is not clear. The expression
pattern of murine CR1 is for the most part similar to
that of human CR1 except that mouse RBCs do not
express CR1.41 To date, no individuals completely
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Fig. 1. The complement system. The classical pathway is activated by
antigen-antibody complex and the alternative and lectin
pathways by microbial surfaces. Activation of these pathways
results in the generation of the key enzymes, C3 and C5
convertases, which in turn results in the release of C3a, C4a, and
C5a anaphylatoxins (inflammatory response), C3b (opsonization
of target cells), and the generation of the membrane attack
complex in the target cell (lysis). The different steps of the
cascade where CR1 inhibits complement activation are shown.
Abbreviations: MBL, mannan-binding lectin; MASP, MBL-associated
serine protease.
Fig. 2. Regulation of complement by decay-accelerating and cofactor
activitiy of CR1. The classical complement inhibitory activity of
CR1 is depicted. CR1 dissociates C3 convertase of the classical
pathway through its decay-accelerating activity. In addition,
through its cofactor activity, it degrades C4b into C4c and C4d.
Central to these activities is its ability to bind C4b. (Adapted from
Hourcade et al.12)
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lacking the CR1 protein have been identified.
However, RBCs that express low copy numbers of CR1
and its associated Knops blood group antigens, known
as the Helgeson phenotype, have been described and
appear to be associated with protection against severe
malaria.42
CR1 Structure
In humans, four allotypes of CR1,varying in size,are
known.43 The predicted amino acid sequence of the
common allotype (CR1*1) is 2039 residues (Fig 3).18,44,45
The extracellular 1930-residue–long domain of CR1,
with 25 potential N-glycosylation sites, can be divided
into 30 short consensus repeats (SCRs), each of 59 to
72 amino acids (aa) with sequence homology between
SCRs ranging from 60 to 90 percent.45 Homologous
SCRs with four conserved cysteine residues are also
found in other RCA members.12 The first 28 SCRs of
CR1 are further arranged into four longer regions of
similarity, termed long homologous repeats (LHRs A
through D), consisting of seven SCRs each18,44 (Fig. 3).
In mice, CR1 is expressed along with the alternatively
spliced gene product CR2.46–48 Murine CR1 consists of
21 SCRs, with 15 SCRs identical to murine CR2 and 6
unique SCRs at the amino terminus.46–48
CR1-Based Therapeutics
The complement regulatory function of CR1 has
been exploited for development of a potent anti-
complement agent. Specifically, a recombinant soluble
form of CR1 (sCR1), by binding C3b and C4b and
inactivating the convertases, has successfully inhibited
the complement activation cascade and prevented
complement-mediated tissue injury in several animal
models.49,50 More importantly, sCR1 has been in human
clinical trials for the treatment of acute respiratory
distress syndrome and to reduce tissue damage in
myocardial infarction and lung transplantation,51–53 with
possible favorable outcomes.52 Despite the role of CR1
as a global inhibitor of complement activation, the
antibacterial defenses of the patients undergoing
treatment have not, thus far, been compromised,
underscoring the usefulness of sCR1 as a therapeutic
agent.53 It is important to note that there are currently
no anticomplement therapeutics in the clinic. Indeed,
sCR1 represents the best in vivo characterized
anticomplement agent to date.
Our studies are the first to demonstrate a potential
for sCR1 for inhibiting complement-mediated RBC
destruction following transfusion immunization
events.53,54 Furthermore, through structure-function
analysis we have identified a 254-aa domain at the N-
terminus of CR1, consisting of four SCRs and one-
eighth of sCR1, that has antihemolytic activity in vivo.
Previous in vitro studies by us and others demonstrated
that the N-terminal domain of CR1 has barely any
cofactor activity, but has decay-accelerating activity for
the C3 convertases and inhibits the classical activation
pathway.54,56–61 Moreover, we and others have shown
that the four N-terminal SCRs preferentially bind
C4b.45,56,59,62–64 Based on these observations, we believe
that fine mapping of the C4b binding and the decay-
accelerating activity (C4b.2a) for the classical
activation pathway in the 254-aa domain will lead to
future design of nonimmunogenic small molecule
inhibitors to down-regulate complement-mediated
RBC destruction. It is important to note that chronic
treatment with complement inhibitors is likely to
undermine the body’s ability to fight infections65 and
may lead to development of autoimmune diseases
(discussed in a later section). The application for these
inhibitors is thus for short-term prophylactic use
before transfusion of not fully matched blood in
emergency situations and as a therapeutic option in
select patients with complement-mediated immune
hemolysis to ameliorate the life-threatening
complications.
Complement and AIHA
AIHA is an autoimmune disease caused by
autoantibodies against RBC self-antigens, causing
Fig. 3. Schematic representation of the common isotype of CR1.The 30
SCRs are represented by blocks.Groups of seven SCRs are further
subdivided into four LHRs. The ligand binding sites for C3b and
C4b are shaded. The preferred ligand is in bold; the alternative
ligand is in parentheses.The positions of C1q/MBL binding sites
have not yet been defined.
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shortened RBC survival.6 The underlying mechanism
for breakdown of immunologic tolerance is not well
established. Several lines of evidence support the role
of complement in the maintenance of tolerance to self-
antigens: (1) Hereditary deficiencies of complement
proteins of the classical pathway have been associated
with autoimmune diseases.66 For example, 90 percent
of C1q-deficient patients develop autoimmune
disease,67 and C1q knockout mice have a high
incidence of developing autoimmune disease.68 (2)
Altered levels of expression of CR1 have been observed
in patients with AIHA as well as other autoimmune
diseases, such as systemic lupus erythematosus,
rheumatoid arthritis, Sjogren’s syndrome, and some
diabetic patients.69–77 In a mouse model of severe
lupus-like disease (MRL/lpr), lower levels of CR1/CR2
receptors have been found on B cells before the
development of disease manifestations,78 suggesting
that altered complement receptor expression may
contribute to initiation or progression of autoimmune
disease. Gene knockout studies of mice lacking CR1
(along with the alternatively spliced gene product
CR2) indicate that CR1 and CR2 control the activation
thresholds of B cells to self-antigens,79 although the
exact molecular mechanism is not clearly understood.
Because CR1/CR2 knockout mice lack both CR1 and
CR2, the specific contribution of each receptor cannot
be dissected. However, mice deficient in C4, but not
C3, have a phenotype similar to CR1/CR2-deficient
mice in studies demonstrating their role in immune
tolerance, strongly suggesting that the primary effect in
these mice is mediated by CR1.79 (3) C3b was recently
shown to induce the development of T-regulatory cells,
known to be important for maintenance of peripheral
tolerance (discussed in a later section). Specifically, it
was shown that membrane cofactor protein (MCP,
CD46), a natural complement regulatory protein
whose ligands are C3b and C4b,80 can act as a
coreceptor for inducing the development of IL-
10–secreting CD4+CD25+ regulatory T cells, which are
responsible for active suppression of autoreactive T
cells.81
T-Regulatory Cells
T-regulatory cells (Tregs) are a subset of T cells that
function to control immune responses, including those
directed against self-antigens. Different populations of
Tregs have been described, including thymically
derived naturally occurring cells and those that are
induced in the periphery through exposure to
antigen.82,83 Naturally occurring Tregs constitute about
1 to 2 percent of peripheral blood mononuclear cells,
or about 5 to 10 percent of the CD4+ T cells, and are
characterized by coexpression of CD25 (α subunit of
IL-2 receptor) and the transcriptional repressor FoxP3
(forkhead box P3).84 Their role in maintenance of self-
tolerance and their ability to suppress a number of
autoimmune diseases has attracted a great deal of
attention and opened the possibility of developing
novel immunotherapeutic strategies for suppression of
autoimmunity.84,85 Nevertheless, many questions
remain to be answered about the characteristics and
biology of Tregs. For example, it is not known whether
the suppressive activity of the CD4+CD25+ Tregs can be
subdivided to smaller subpopulations or whether
smaller individual CD4+CD25+ Tregs have different
degrees of suppressive activity.86 Supporting this
possibility, CD103+ T cells within CD4+CD25+ Tregs
were shown to have more suppressive activity than
CD103–CD4+CD25+ Tregs and CD62Lhigh expressing
CD4+CD25+ Tregs appear more potent in preventing
certain autoimmune diseases in mice.87,88 Preliminary
studies in my laboratory indicate that CR1 is indeed
expressed on a subpopulation of CD4+CD25+ Tregs.
The molecular basis of the mechanism of Treg cell-
mediated suppression is not fully known, although the
consensus is that they can expand and augment their
suppressive activity when stimulated.89,90 In vitro
naturally occurring CD4+CD25+ mediate suppression of
cocultured CD25- T cells by cell-cell interactions, not
by cytokines.91–94 Activation has been shown to occur
through TCR-specific signals.90,95–97 Interestingly, non-
TCR–specific stimuli such as bacterial products
through Toll-like receptor 4 have also been shown to
activate CD4+CD25+ Tregs.98 Given that innate immune
responses such as Toll-like receptors can stimulate
Tregs, it is conceivable, although as yet untested, that
complement activation products, through interactions
with complement receptors such as CR1, may also be
involved in augmenting or attenuating the activation
state of Tregs, with consequences for their suppressive
activity. In support of this possibility, C3b-CD46
interactions were recently shown to activate a subset
of Tregs, namely the inducible Tregs.81 Preliminary
studies from my laboratory indicate that CR1 can also
mediate the suppressive activity of CD4+CD25+ Tregs,
although the exact mechanism of suppression is still
under investigation.
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Possible Role of Complement/CR1 in Treg
Induction
We speculate that after certain infections,
complement is activated and foreign antigens that are
opsonized with complement components C3b and
C4b, which are known to be the ligands for CR1 and
CD46, may induce regulatory T cells. Thus, the initial
complement activation will help clear the pathogen by
direct lysis, inflammatory response, phagocytosis of
complement-sensitized infectious agent, or a
combination of these (Fig. 1). In our hypothetical
model, complement activation through induction of
Tregs will also result in suppression of certain self-
reactive lymphocytes as well as effector T cells that
would normally cause infection-induced immunopa-
thology (Fig. 4). Given that complement is so tightly
regulated,1 it is conceivable that many factors,
including the nature and strength of the activators
(pathogens), will determine the balance among
complement activation, Treg induction, and T-cell
suppression. Our model obviously does not preclude
the role of other mediators besides complement
activation products for Treg activity,which may explain
why certain infections persist or become chronic99 and
are correlated with lower incidence of auto-
immunity.100 Nevertheless, complement deficiencies,
which we propose can cause decreased Treg activity,
are associated with autoimmune disease.67,101 AIHA
appears to be a secondary complication in patients
with a range of diseases, including those with viral or
mycoplasmal infections,102 and the presence of cross-
reactive foreign antigens may be the underlying
mechanism for breakdown of tolerance in these
patients.103 It is interesting to note that Rh antibodies
do not fix complement on RBCs. In warm-type AIHA,
many of the autoantibodies are directed against the Rh
complex.6 It may be that antigens such as Rh that are
not initially opsonized with complement components
may not be subject to immune tolerance. Thus, upon
stimulation with cross-reactive foreign antigens,
autoreactive T cells specific to Rh antigens are
preferentially expanded, resulting in AIHA. Future
studies are needed to further explore the potential
contribution of CR1 and its ligands in the development
of AIHA.
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